Dr. William Makis writes in https://x.com/MakisMD/status/1956751625051341079

BREAKING NEWS: Our FENBENDAZOLE in Cancer Paper has been Published! Largest cancer patient publication since the 2021 Stanford Paper - three Stage 4 Cancer patients take Fenbendazole and are now in remission! No chemo!

This is making news around the world. 😃

Our Fenbendazole paper passed peer review and is now published! Three Stage 4 Cancer patients take Fenbendazole successfully and are now Cancer free without chemo.

Case 1: 83 year old woman with Stage 4 Breast Cancer (recurrence free for 3 years now)

Case 2: 75 year old man with Stage 4 Prostate Cancer (recurrence free for 2 years now)

Case 3: 63 year old man with Stage 4 Melanoma (recurrence free for 11 months now)

"All three patients tolerated FBZ without any reported adverse effects and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years"

"FBZ demonstrates potential as a novel promising therapeutic option for repurposing in Oncology"

The paper was published by William Makis, Ilyes Baghli, Pierrick Martinez in Case Reports in Oncology (2025), Volume 18 Issue 1.

"Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients"

https://karger.com/cro/article/18/1/856/927630

"Abstract

Background: Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited. Case Presentations: This report highlights 3 cases of patients with advanced cancer – including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ without any reported adverse effects, and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years. Conclusion: FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use."